Selected Publications & Patents

• Synergistic FRET assays for drug discovery targeting RyR2 channels.
Rebbeck R, Ginsburg KS, Ko CY, Fasoli A, Rusch K, Cai GF, Dong X, Thomas DD, Bers DM, Cornea RL. 
Journal of Molecular and Cellular Cardiology. 2022.

ABSTRACT

• Cardiac ryanodine receptor N-terminal region biosensors identify novel inhibitors via FRET-based high-throughput screening.
Zhang J, Singh DP, Ko CY, Nikolaienko R, Wong King Yuen SM, Schwarz JA, Treinen LM, Tung CC, Rožman K, Svensson B, Aldrich CC, Zima AV, Thomas DD, Bers DM, Launikonis BS, Van Petegem F, Cornea RL. 
Journal of Biological Chemistry. 2021.

ABSTRACT

• CaMKIIδ post-translational modifications increase affinity for calmodulin inside cardiac ventricular myocytes.
Simon M, Ko CY, Rebbeck RT, Baidar S, Cornea RL, Bers DM. 
Journal of Molecular and Cellular Cardiology. 2021.

ABSTRACT

• Potent inhibitors of toxic alpha-synuclein identified via cellular time-resolved FRET biosensors.
Braun AR, Liao EE, Horvath M, Kalra P, Acosta K, Young MC, Kochen NN, Lo CH, Brown R, Evans MD, Pomerantz WCK, Rhoades E, Luk K, Cornea RL, Thomas DD, Sachs JN. 
NPJ Parkinsons Disease. 2021.

ABSTRACT

• Structural basis for allosteric control of the SERCA-Phospholamban membrane complex by Ca2+ and phosphorylation.
Weber DK, Reddy UV, Wang S, Larsen EK, Gopinath T, Gustavsson MB, Cornea RL, Thomas DD, De Simone A, Veglia G. 
eLife. 2021.

ABSTRACT

• The transmembrane peptide DWORF activates SERCA2a via dual mechanisms.
Li A, Yuen SL, Stroik DR, Kleinboehl E, Cornea RL, Thomas DD. 
Journal of Biological Chemistry. 2021.

ABSTRACT

• Met125 is essential for maintaining the structural integrity of calmodulin's C-terminal domain.
Nelson SED, Weber DK, Rebbeck RT, Cornea RL, Veglia G, Thomas DD. 
Sci Rep. 2020.

ABSTRACT

• The functional significance of redox-mediated inter subunit cross-linking in regulation of human type 2 ryanodine receptor.
Nikolaienko R, Bovo E, Rebbeck RT, Kahn D, Thomas DD, Cornea RL, Zima AV. 
Redox Biology. 2020.

ABSTRACT

• Live-cell cardiac-specific high-throughput screening platform for drug-like molecules that enhance Ca2+ transport.
Schaaf TM, Kleinboehl E, Yuen SL, Roelike LN, Svensson B, Thompson AR, Cornea RL, Thomas DD. 
Cells. 2020.

ABSTRACT

• Resolved structural states of calmodulin in regulation of skeletal muscle calcium release.
McCarthy MR, Savich Y, Cornea RL, Thomas DD. 
Biophysical Journal. 2020.

ABSTRACT

• RyR1-targeted drug discovery pipeline integrating FRET-based high-throughput screening and human myofiber dynamic Ca2+ assays.
Rebbeck RT, Singh DP, Janicek KA, Bers DM, Thomas DD, Launikonis BS, Cornea RL. 
Nature Scientific Reports. 2020.

ABSTRACT

•Mechanical factors tune the sensitivity of ​mdx muscle to eccentric strength loss and its protection by antioxidant and calcium modulators.
Lindsay A, Baumann CW, Rebbeck RT, Yuen SL, Southern WM, Hodges JS, Cornea RL, Thomas DD, Ervasti JM, Lowe DA. 
Skeletal Muscle. 2020.

ABSTRACT

• Viral expression of a SERCA2a-activating PLB mutant improves calcium cycling and synchronicity in dilated cardiomyopathy hiPSC-CMs.
Stroik D, Ceholski DK, Bidwell PA, Mleczko J, Thanel PF, Kamdar F, Autry JM, Cornea RL, Thomas DD. 
Journal of Molecular and Cellular Cardiology. 2019.

ABSTRACT

Patents

U.S. patent 8,431,356:  Fluorescence resonance energy transfer assays for sarco/endoplasmic reticulum calcium ATPase and phospholamban (inventors: David D. Thomas, Razvan L. Cornea, Krisztina M. Zsebo). Issued April 30, 2013.

U.S. patent 10,281,476: FRET-based high-throughput screening methods to discover modulators of RyR calcium channels (inventors: Razvan L. Cornea, Donald M. Bers, David D. Thomas, Gregory D. Gillispie). Issued May 7, 2019. 

U.S. patent 10794898: High-throughput, high-precision methods for detecting protein structural changes in living cells (inventors, David D. Thomas, Simon J. Gruber, Razvan L. Cornea, Gregory D. Gillispie, Seth L. Robia). Issued October 6, 2020.